Souhaitez-vous accéder aux communiqués récents ?

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients...

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH ...

Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval Steady-state pharmacokinetic findings provide mechanistic...

Crohn’s and Colitis Canada and AbbVie open applications for the 2026 AbbVie IBD Scholarship, marking 15 years of supporting students living with IBD.

TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et Colite Canada et AbbVie sont heureux d'annoncer l'ouverture des candidatures pour le Programme de bourses d'études MII d’AbbVie 2026. Cette année...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis...

New York, March 03, 2026 (GLOBE NEWSWIRE) -- [New York, NY, and Riyadh, Saudi Arabia [March 3, 2026] — Mount Sinai and King Saud University Medical City in Riyadh, Saudi Arabia, today announced a...

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX)...

Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights,...

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at...